100 Plus Studies Concur – Cannabis Beats Cancer, Yet It’s Still Not Legal

Ganja
Phillip Schneider via Waking Times:

In 1996, California was the first state to legalize the use of Cannabis for medicinal purposes. Since then, the past decade has been ripe with research into the potential medicinal benefits of Cannabis. During this time we have learned that Cannabis can potentially treat such an enormous list of illnesses that the justification for its status as a schedule 1 illegal drug is being called into question.

Proponents of medical marijuana claim that cannabis can be used to treat over 150 different ailments such as sleep disorders, anxiety disorders, back pain, shingles, epilepsy, seizures, Chrohn’s disease, restless leg syndrome, PTSD, MS, autoimmune disease, autism, alcoholism and much more. Because of this, cannabis is being dubbed the ‘miracle drug’ by many, including the parents of children who have suffered from seizures and other debilitating diseases, only to be saved or seriously aided by the use of cannabis compounds.

But cannabis is not only a treatment for seizures and back pain. Another exciting area of research is the potential for cannabis in treating cancer. There have been over a hundred scientific studies which conclude that cannabis compounds can play a vital role in the treatment cancer, with multiple documented cases proving this to be true. The National Cancer Institute even admits that “Cannabinoids may have benefits in the treatment of cancer-related side effects.”

One study titled, ‘Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors’ states in part that “activation of cannabinoid receptors induced the apoptotic death of tumorigenic epidermal cells”. It goes on:

“Local administration of the mixed CB(1)/CB(2) agonist WIN-55,212-2 or the selective CB(2) agonist JWH-133 [cannabinoids] induced a considerable growth inhibition of malignant tumors generated by inoculation of epidermal tumor cells into nude mice. Cannabinoid-treated tumors showed an increased number of apoptotic cells. This was accompanied by impairment of tumor vascularization, as determined by altered blood vessel morphology and decreased expression of proangiogenic factors” and concludes “These results support a new therapeutic approach for the treatment of skin tumors.”

Another study concludes that “CB(2) receptors could be used for developing innovative therapeutic strategies against breast cancer.”

Continue reading.